Marchenko Danevych has advised U.S.-based Fortune Global 500 Company and its European and Ukrainian subsidiaries on jurisdiction, merits and strategy of investment arbitration and investor-state negotiations with Ukraine and its Government. link

Team is advising Global Top 25 Pharmaceutical and Biotech Company on various legal aspects of medicines pricing, procurement and reimbursement reform, introduction of the National Essential Medicines List and expected transformation in state funding of rare diseases treatment. link

Marchenko Danevych team advises a global healthcare leader Lilly on a number of simplified marketing authorization procedures recently introduced in Ukraine. link

As part of a consortium of international experts established and financed by EBRD, Marchenko Danevych’s lawyers applied their expertise to the unprecedented attempt to improve the medicines registration system of Ukraine. link

Marchenko Danevych advised a large Ukrainian manufacturing company engaged in supplies and business operations globally on important issues and general defense strategy. link

Marchenko Danevych has successfully defended a group trading subsidiary of one of the Top 5 Global pharmaceutical companies in the competition case conducted by the Antimonopoly Committee of Ukraine. link

This site uses cookies. An explanation of their purpose can be found within Terms of Use